UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review

Haematologica (Roma), 2020-07, Vol.105 (7), p.1914-1924

2020

Volltextzugriff (PDF)

A systematic review of non-standard dosing of oral anticancer therapies

BMC cancer, 2018-11, Vol.18 (1), p.1154-15, Article 1154

2018

Volltextzugriff (PDF)

Clinical outcomes of bortezomib-based therapy in myeloma

PloS one, 2018-12, Vol.13 (12), p.e0208920-e0208920

2018

Volltextzugriff (PDF)

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

Hematology (Luxembourg), 2022-12, Vol.27 (1), p.204-207

2022

Volltextzugriff (PDF)

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

PloS one, 2020-02, Vol.15 (2), p.e0229469-e0229469

2020

Volltextzugriff (PDF)

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Haematologica (Roma), 2020-09, Vol.105 (9), p.e474-479

2020

Volltextzugriff (PDF)

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

PloS one, 2022-01, Vol.17 (1), p.e0262388-e0262388

2022

Volltextzugriff (PDF)

Treat or palliate: outcomes of very elderly myeloma patients

Haematologica (Roma), 2018-01, Vol.103 (1), p.e32-e34

2018

Volltextzugriff (PDF)

Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol

Systematic reviews, 2017-12, Vol.6 (1), p.244-8, Article 244

2017

Volltextzugriff (PDF)

Resource implications of bortezomib therapy in a large UK cohort: An evaluation study

Journal of oncology pharmacy practice, 2019-12, Vol.25 (8), p.1995-1998

2019

Volltextzugriff (PDF)

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events

Expert review of hematology, 2022-06, Vol.15 (6), p.503-517

2022

Volltextzugriff (PDF)

Systematic Review of Non-Conventional Dosing of Oral Anticancer Therapies in Malignant Haematology

Blood, 2018-11, Vol.132 (Supplement 1), p.5915-5915

2018

Volltextzugriff (PDF)

Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID‐19 pandemic

British journal of haematology, 2020-06, Vol.189 (6), p.e224-e227

2020

Volltextzugriff (PDF)

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Blood, 2019-11, Vol.134 (Supplement_1), p.5884-5884

2019

Volltextzugriff (PDF)

Long term outcomes in monoclonal gammopathy of renal significance

British journal of haematology, 2019-09, Vol.186 (5), p.706-716

2019

Volltextzugriff (PDF)

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Haematologica (Roma), 2020-09, Vol.105 (9), p.e474

2020

Volltextzugriff (PDF)

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Journal of clinical oncology, 2023-12, Vol.41 (35), p.5376-5387

2023

Volltextzugriff (PDF)

Optimising Therapeutic Outcomes of Patients with Haematological Malignancies (Multiple Myeloma)

Djebbari, Faouzi

2020

Volltextzugriff (PDF)

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model

PloS one, 2022-01, Vol.17 (1), p.e0262388

2022

Volltextzugriff (PDF)

Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience

British journal of haematology, 2020-02, Vol.188 (4), p.e57-e60

2020

Volltextzugriff (PDF)

Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK)

British journal of haematology, 2021-03, Vol.192 (6), p.e136-e139

2021

Volltextzugriff (PDF)

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Blood, 2019-11, Vol.134 (Supplement_1), p.4768-4768

2019

Volltextzugriff (PDF)

Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: A single centre experience

Annals of oncology, 2017-06, Vol.28, p.iii24-iii25

2017

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Hematology
(24)
Life Sciences & Biomedicine
(22)
Humans
(19)
Myeloma
(10)
Aged
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Chemotherapy
(8)
Female
(8)
Male
(8)
Multiple Myeloma
(8)
Multiple Myeloma - Drug Therapy
(8)
Treatment Outcome
(8)
Aged, 80 And Over
(7)
Bortezomib
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Middle Aged
(6)
Retrospective Studies
(6)
United Kingdom - Epidemiology
(6)
Morbidity
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(6)
British Journal Of Haematology
(6)
Clinical Lymphoma, Myeloma And Leukemia
(5)
Plos One
(5)
European Journal Of Haematology
(4)
Haematologica
(4)
Hematology
(2)
Annals Of Oncology
(1)
Blood Advances
(1)
Bmc Cancer
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review

A systematic review of non-standard dosing of oral anticancer therapies

Clinical outcomes of bortezomib-based therapy in myeloma

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

Treat or palliate: outcomes of very elderly myeloma patients

Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Resource implications of bortezomib therapy in a large UK cohort: An evaluation study

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK‐Wide Real‐World Dataset

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events

Systematic Review of Non-Conventional Dosing of Oral Anticancer Therapies in Malignant Haematology

Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID‐19 pandemic

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Long term outcomes in monoclonal gammopathy of renal significance

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Optimising Therapeutic Outcomes of Patients with Haematological Malignancies (Multiple Myeloma)

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model

Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience

Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK)

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: A single centre experience

Suchergebnisse filtern